<?xml version="1.0" encoding="UTF-8"?>
<ref id="b7-1040797">
 <label>7.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cramer</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Fink</surname>
    <given-names>AM</given-names>
   </name>
   <name>
    <surname>Busch</surname>
    <given-names>R</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group</article-title>. 
  <source>Leuk Lymphoma</source>. 
  <year>2013</year>; 
  <volume>54</volume>(
  <issue>8</issue>):
  <fpage>1821</fpage>â€“
  <lpage>1822</lpage>.
  <pub-id pub-id-type="pmid">23631654</pub-id>
 </mixed-citation>
</ref>
